Echocardiographers with specialized expertise sometimes perform myocardial perfusion imaging using U.S. Food and Drug Administration-approved microbubbles in an off-label capacity, correlating microbubble replenishment in the near field with blood flow through the myocardium. This study reports the in vivo clinical feasibility of a voltage-sensitive ultrasound enhancing agent (UEA) for myocardial perfusion imaging. Four UEAs were injected into Sprague-Dawley rats while ultrasound images were collected to quantify brightness in the left ventricular (LV) cavity, septal wall, and posterior wall in systole and diastole. Formulation IV, a phase change agent nested within a negatively charged phospholipid bilayer, increased the tissue-to-cavity ratio in both systole and diastole in the septal wall, 6 dB, and in the posterior wall, 5 dB, while leaving the LV cavity at baseline. This outcome improves the signal of the myocardium relative to the LV cavity and shows promise as a myocardial perfusion UEA.

具有专业知识的超声心动图技师有时会使用美国食品和药物管理局批准的微泡以标签外的能力进行心肌灌注成像，将近场中的微泡补充与通过心肌的血流相关联。本研究报告了体内电压敏感超声增强剂（UEA）用于心肌灌注成像的临床可行性。将四种 UEA 注射到 Sprague-Dawley 大鼠中，同时收集超声图像以量化收缩期和舒张期左心室 (LV) 腔、间隔壁和后壁的亮度。配方 IV 是一种嵌套在带负电荷的磷脂双层中的相变剂，在离开 LV 腔的同时，使间隔壁收缩期和舒张期的组织腔比增加了 6 dB，后壁增加了 5 dB在基线。这一结果改善了心肌相对于 LV 腔的信号，并显示出作为心肌灌注 UEA 的前景。